
Statistically significant PhI results for GLP-1/glucagon dual agonist
MetaVia has announced positive statistically significant results from the eight-week, non-titrated 48mg, multiple ascending dose (MAD) cohort of its Phase I clinical trial of DA-1726. DA-1726 is a novel, dual oxyntomodulin (OXM) analogue agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for… Read More












